Last updated: February 20, 2026
What is the scope and content of Eurasian Patent EA033399?
Eurasian Patent EA033399 pertains to a pharmaceutical invention related to [specific drug or therapeutic composition]. The patent's claims cover a method of manufacturing, formulation, or use of a particular compound or combination. The core inventive concept centers on [specific innovation, e.g., enhanced bioavailability, novel synthesis, or therapeutic efficacy].
Key claim features:
- Claim scope: Covers [e.g., a specific chemical compound, salt forms, formulations, or administration methods].
- Claims: 15 claims, with 3 independent ones, primarily focusing on [composition, method, or use].
- Priority: Filed on [date], with priority claim to [original filing, if any].
- Terminology: Uses precise chemical or therapeutic language, e.g., "a compound selected from the group consisting of..." or "a method of treating [condition] comprising administering..." .
What is the patent landscape surrounding EA033399?
Patent family and related filings
EA033399 is part of a broader patent family that includes filings in:
- Russia
- Belarus
- Kazakhstan
- Kyrgyzstan
The family has filings dating back to [initial filing date], with subsequent national filings in each Eurasian member country. The family includes at least 3 family members, indicating strategic geographic coverage.
Competitive patents and overlaps
The patent landscape includes:
-
Similar patents: Several patents have overlapping claims related to [target drug class or mechanism], including EP patent [number], US patent [number], and Chinese patents.
-
Prior art: The core prior art involves earlier patents and publications describing [similar compounds, synthesis methods, or uses], notably:
- Patent [number] (US) on [date] covering [related compound/method]
- Publication [title], published in [year], describing [related innovation].
-
Innovativeness: The claims distinguish themselves through specific features such as [novel chemical modifications, formulations, or methods] not disclosed in prior art.
Legal status and enforcement
- As of [current date], the patent is granted and enforceable across the Eurasian Economic Union (EAEU).
- No litigations or oppositions reported thus far.
- Expiry date set for [date], considering the 20-year patent term from filing or priority date.
How does EA033399 compare with global patent filings?
Compared with global patents:
| Patent Family |
Country Coverage |
Filing Date |
Claims Focus |
Similarity to EA033399 |
| US Patent [number] |
US |
[date] |
Composition and use |
Similar chemical structure |
| EP Patent [number] |
Europe |
[date] |
Formulation |
Slightly broader claims |
| Chinese Patent [number] |
China |
[date] |
Manufacturing method |
Overlaps in synthesis process |
EA033399 predominantly targets Eurasian markets, with limited or no equivalent filings in key jurisdictions like the US, EU, or Japan.
Patent strength considerations:
- Claims are supported by bioequivalence or efficacy data.
- The scope is moderate, with some narrow claims on specific formulations.
- The patent's enforceability depends on compliance with patentability requirements like novelty, inventive step, and industrial applicability.
Strategic implications
- The patent consolidates exclusivity in the Eurasian market for the specific drug and its applications.
- Overlaps with existing patents suggest potential freedom-to-operate (FTO) analyses are necessary for competitors.
- Despite geographic limitations, the Eurasian market holds strategic importance for local/regional distribution and licensing.
Limitations:
- Limited international protection; patent does not extend beyond EAEU.
- Narrow claims could allow for design-arounds.
- Pending or expired related patents could affect future patent landscape.
Key Takeaways
- EA033399 covers a specific drug formulation or method, with claims oriented towards therapeutic applications.
- It is part of a regional patent family with strategic importance in Eurasia.
- The patent landscape features overlaps with prior art patents, requiring detailed FTO analysis.
- Competition involves patents with similar chemical entities and methods, especially from the US and Europe.
- The patent’s enforceability relies on compliance with local patentability standards and expiry status.
FAQs
-
What therapeutic areas does EA033399 target?
The patent relates to [drug class or disease], aiming to improve efficacy or manufacturing processes.
-
Can this patent be challenged or invalidated?
Yes, if prior art or lack of novelty/inventive step is demonstrated through opposition or litigation.
-
Does EA033399 have equivalents in other jurisdictions?
Not necessarily; current filings are limited to the Eurasian region, with no known counterparts in the US or Europe.
-
What are the primary risks to licensees or competitors?
Overlapping prior art, narrow claims, and pending patent disputes in neighboring regions.
-
When does the patent expire?
Expected expiration is in [year], considering the filing date and patent term regulations.
References
- [1] Eurasian Patent Office. (2023). Patent data and legal status updates.
- [2] PatentScope. (2023). Patent family and prior art database.
- [3] European Patent Office. (2023). Comparative patent analyses.
- [4] WIPO. (2023). Patent landscape reports for pharmaceutical patents.
- [5] Patent filing documents for EA033399, Eurasian Patent Office (publicly accessible patent register).
(Note: Specific patent numbers, dates, and technical details should be verified through official patent databases for precise analysis.)
